Nanosized Trojan horses created from a patient’s own immune cells have successfully treated inflammation by overcoming the body’s complex defense mechanisms, perhaps leading to broader applications for treating diseases characterized by inflammation, such as cancer and cardiovascular diseases.
An international team, led by researchers at Houston Methodist Research Institute, described the creation of nanoparticles called leukosomes and evaluated their ability to treat localized inflammation in the May 23 issue of Nature Materials (early online).
Recent approaches to treating inflammatory diseases have been unsuccessful because an already overactive immune system treats simple nanoparticles as foreign invaders and clears them from the body, preventing them from reaching their target.
“A better approach for building effective drug delivery platforms is to find inspiration for their design in the composition of the immune cells of our body,” said Ennio Tasciotti, Ph.D., director of the Center for Biomimetic Medicine at Houston Methodist Research Institute and the paper’s senior author. “Immune cells such as leukocytes freely circulate in blood vessels, recognize inflammation, and accumulate in inflamed tissues. They do so by using special receptors and ligands on their surface. We purified leukocytes from a patient, then integrated their special ligands and receptors into the leukosome surface. Using the body’s own materials, we built a drug delivery system camouflaged as our own body’s defense system—thus the Trojan horse.”
In its normal form, acute inflammation is a necessary and beneficial part of the body’s defense against infection. However, under certain conditions, inflammation can turn from a friend to a vicious foe, damaging or destroying healthy cells. This is the case for autoimmune disorders such as rheumatoid arthritis, lupus and inflammatory bowel disease, or in illnesses such as Alzheimer’s, cancer, cardiovascular disease and Type 2 diabetes.
Leukosomes are able to target inflamed tissues because they retain the same surface properties of the immune cell membranes from which they are made. To evaluate leukosomes’ effectiveness as drug carriers, Tasciotti and his colleagues created vesicles from mouse leukocytes and filled them with dexamethasone (DXM), an anti-inflammatory agent.
“We used ‘personalized’ DXM-loaded leukosomes to treat inflammation in mice,” Tasciotti said. “After administering the leukosomes, we observed their attachment to the surface of blood vessels surrounding the inflamed tissue, and they selectively delivered DXM to the affected cells.”
The treated mice showed definite signs of improvement, including resolution of the inflammation, a significant reduction in tissue thickness, and a reversal of the immune response that is commonly seen in inflammation.
The success of the team’s initial leukosome trial is encouraging, Tasciotti said, and suggests that membranes purified from any other cell types could also be used as biomimetic nanocarriers to treat other diseases.
“By combining cell biology with nanotechnology, we can create valuable medical tools that work within, and not around, the laws of nature,” he said.
Learn more: Nanoscale trojan horses treat inflammation
The Latest on: Treating inflammation
via Google News
The Latest on: Treating inflammation
- Common treatment for MIS-C patients likely works by depleting neutrophilson October 15, 2021 at 5:59 pm
Intravenous immune globulin (IVIG) — a common treatment for multisystem inflammatory syndrome in children (MIS-C) — likely works by depleting immune cells called neutrophils, according to a recent ...
- Patent Infringement Suit Against Bristol-Myers, Celgene Targets Multiple Sclerosis Treatmenton October 15, 2021 at 1:12 pm
Bristol-Myers Squibb and Celgene, a drug manufacturer specializing in treatments for cancer and inflammatory diseases, were hit with a patent infringement lawsuit Friday in New Jersey District Court.
- Antibody treatment for MIS-C works by depleting inflammatory immune cellson October 15, 2021 at 10:35 am
Intravenous immune globulin (IVIG)—a common treatment for multisystem inflammatory syndrome in children (MIS-C)—likely works by depleting immune cells called neutrophils, according to a recent study ...
- Media Advisory: Antibody treatment for MIS-C works by depleting inflammatory immune cellson October 15, 2021 at 5:00 am
WHAT: Intravenous immune globulin (IVIG)—a common treatment for multisystem inflammatory syndrome in children (MIS-C)—likely works by depleting immune cells called neutrophils ...
- Pfizer’s Abrocitinib Receives Positive CHMP Opinion for the Treatment of Adults with Moderate to Severe Atopic Dermatitison October 15, 2021 at 4:50 am
Pfizer Inc. (NYSE: PFE) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the 100 mg and 200 ...
- Akeso is Rapidly Advancing The Phase II Clinical Trial of IL-4R Monoclonal Antibody (AK120) for the Treatment of Atopic Dermatitis and Asthmaon October 14, 2021 at 9:44 pm
Akeso, Inc. (the Company, 9926.HK) announces that the Company's self-developed innovative drug candidate, IL-4R monoclonal antibody (AK120), was approved by the Center for Drug Evaluation (CDE) of the ...
- Researchers try using 'bubbles' to treat inflammationon October 12, 2021 at 12:01 pm
In experiments with mice, a team uses extracellular vesicles equipped with specific proteins on the surface to reduce three types of inflammation.
- 10 Top Idiopathic Inflammatory Myopathy Treatment Market to Watchon October 12, 2021 at 6:10 am
The demand for effective treatment for urological abnormalities such as prostate cancer is increasing primarily due to rapid changes in lifestyle,” stated a lead analyst at Fortune ...
- 5 Key Trends in the Idiopathic Inflammatory Myopathy Treatment Market Industry for 2021 and Beyondon October 11, 2021 at 10:30 pm
Global Idiopathic Inflammatory Myopathy Treatment Market | 2021 Global Healthcare Industry Analysis To 2028, is ...
- Systemic inflammation linked to symptom-specific depression effectson October 11, 2021 at 2:20 pm
Systemic inflammation appeared to have symptom-specific rather than generalized effects on depression, according to results of a random-effects pooled analysis published in American Journal of ...
via Bing News